Skip to content

Dose-Response Study of Phenylephrine and Norepinephrine for the Treatment of Hypotension during Spinal Anaesthesia for Caesarean Section

Study of Phenylephrine and Norepinephrine for the Treatment of Hypotension during Spinal Anaesthesia

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14005206
Enrollment
Unknown
Registered
2014-09-10
Start date
2014-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension

Interventions

Two groups:Phenylephrine 60-200mcg 2 minutes Norepinephrine 4-12mcg 2 minutes

Sponsors

Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 999 Years

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists Physical Status 1 or 2 non-labouring normotensive parturients with term singleton pregnancies who are scheduled for elective or semi-elective Caesarean section and who have been judged suitable and have agreed to have spinal anaesthesia according to usual clinical criteria, baseline systolic blood pressure 90–140 mmHg.

Exclusion criteria

Exclusion criteria: Known fetal abnormality, pre-existing or pregnancy-induced hypertension, known cardiovascular or cerebrovascular disease, thrombocytopaenia, coagulopathy, or any medical contraindication to spinal anaesthesia, known allergy to phenylephrine or norepinephrine, weight less than 50 kg or more than 100 kg, height shorter than 140 cm or longer than 180 cm, inability or refusal to give informed consent, age younger than 18 years.

Design outcomes

Primary

MeasureTime frame
Systolic blood pressure 1 minute after drug administration;

Countries

China

Contacts

Public ContactProfessor W. Ngan Kee
warwick@cuhk.edu.hk+852 26322735

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026